Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
Department of Radiation Oncology, Nantong Tumor Hospital, Affiliated Tumor Hospital of Nantong University, Nantong, China.
Cancer Med. 2023 Mar;12(6):6477-6487. doi: 10.1002/cam4.5416. Epub 2022 Nov 22.
This single-center retrospective clinical study aimed to evaluate the efficacy and feasibility of chemoradiotherapy with paclitaxel liposome plus cisplatin for locally advanced esophageal squamous cell carcinoma (ESCC).
Patients with locally advanced ESCC treated with paclitaxel-liposome-based chemoradiotherapy between 2016 and 2019 were retrospectively analyzed. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier analysis.
Thirty-nine patients with locally advanced ESCC were included in this study. The median follow-up time was 31.5 months. The median OS time was 38.3 (95% confidence interval [CI]: 32.1-45.1) months, and the 1-, 2-, and 3-year OS rates were 84.6%, 64.1%, and 56.2%, respectively. The median PFS time was 32.1 (95% CI: 25.4-39.0) months, and the 1-, 2-, and 3-year PFS rates were 71.8%, 43.6%, and 43.6%, respectively. The most common Grade IV toxicity was neutropenia (30.8%) followed by lymphopenia (20.5%). There were no cases of Grade III/IV radiation pneumonia, and four patients (10.3%) had Grade III/IV esophagitis.
Chemoradiotherapy using paclitaxel liposome and cisplatin is a well-tolerated and effective treatment regimen for locally advanced ESCC.
本单中心回顾性临床研究旨在评估紫杉醇脂质体联合顺铂化疗放疗治疗局部晚期食管鳞癌（ESCC）的疗效和可行性。
回顾性分析了 2016 年至 2019 年期间接受紫杉醇脂质体为基础的放化疗的局部晚期 ESCC 患者。采用 Kaplan-Meier 分析评估总生存期（OS）和无进展生存期（PFS）。
本研究纳入了 39 例局部晚期 ESCC 患者。中位随访时间为 31.5 个月。中位 OS 时间为 38.3（95%置信区间[CI]：32.1-45.1）个月，1、2、3 年 OS 率分别为 84.6%、64.1%和 56.2%。中位 PFS 时间为 32.1（95%CI：25.4-39.0）个月，1、2、3 年 PFS 率分别为 71.8%、43.6%和 43.6%。最常见的 4 级毒性是中性粒细胞减少（30.8%），其次是淋巴细胞减少（20.5%）。无 3/4 级放射性肺炎病例，有 4 例（10.3%）患者发生 3/4 级食管炎。
紫杉醇脂质体联合顺铂化疗放疗是治疗局部晚期 ESCC 安全且有效的治疗方案。
